Nasal midazolam effects on childhood acute seizures

J Child Neurol. 2000 Dec;15(12):833-5. doi: 10.1177/088307380001501219.

Abstract

Sixteen children, aged from 2 months to 14 years, with a diagnosis of acute seizures and seen at Dr. Sami Ulus Child Health and Disease Center, were included in this study. Midazolam (5 mg/mL) 0.2 mg/kg was administered intranasally in 30 seconds by an injector. The heart rate, respiratory rate, blood pressure, and oxygen saturation were recorded at 0, 5, and 10 minutes after administration. The seizures of three (18.7%) patients terminated within 1 minute, of seven (43.7%) patients in 1 to 2 minutes, and of three (18.7%) patients in 2 to 5 minutes. However, three (18.7%) patients did not respond to treatment. As a result, it was concluded that intranasal midazolam administration is easy and effective. The half-life of midazolam is shorter than diazepam, and midazolam has fewer complications when compared with diazepam. It is easier to use in nasal drop and spray forms.

Publication types

  • Clinical Trial

MeSH terms

  • Administration, Intranasal
  • Adolescent
  • Child
  • Child, Preschool
  • Female
  • GABA Modulators / administration & dosage*
  • GABA Modulators / pharmacokinetics
  • GABA Modulators / pharmacology
  • Half-Life
  • Humans
  • Infant
  • Male
  • Midazolam / administration & dosage*
  • Midazolam / pharmacokinetics
  • Midazolam / pharmacology
  • Seizures / drug therapy*
  • Treatment Outcome

Substances

  • GABA Modulators
  • Midazolam